{"id":"W2899428983","doi":"10.1182/blood-2018-99-110563","title":"The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Vincristine; CHOP; Oncology; Anaplastic large-cell lymphoma; Chemotherapy regimen; Prednisone; Phases of clinical research; Lymphoma; Cyclophosphamide; Chemotherapy; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003340876,0.001761387,0.002703403,0.0003722223,0.0004181193,0.001289804,0.001128861,0.001867332,0.005448141],"category_scores_gemma":[0.002114472,0.0005187802,0.001745219,0.0003068133,0.001231136,0.001697457,0.0004497526,0.003376519,0.001083275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008474091,"about_ca_system_score_gemma":0.0007838689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005756793,"about_ca_topic_score_gemma":0.001234571,"domain_scores_codex":[0.9990039,0.0005899265,0.00004585626,0.0001877541,0.0000604344,0.0001121837],"domain_scores_gemma":[0.9985978,0.0004219913,0.0002909558,0.0001436843,0.0000997895,0.0004457692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9842164,0.005139066,0.0003944531,0.0002688995,0.0005169059,0.00003301821,0.00003429486,0.0002400719,0.001557589,0.00007800283,0.0004997771,0.007021497],"study_design_scores_gemma":[0.9566747,0.04078708,0.001068054,0.0000189832,0.0002425043,0.00003241644,0.00001395299,0.0003147314,0.0002796672,0.0001401017,0.0004169757,0.00001092193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844929,0.004841856,0.0008303593,0.0008206735,0.00055571,0.003777837,0.001889366,0.0001707103,0.002620528],"genre_scores_gemma":[0.9827257,0.001950186,0.001914278,0.001432052,0.0005009993,0.0042971,0.002529713,0.00005087957,0.004599005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005448141,"threshold_uncertainty_score":0.01822585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02499203716823322,"score_gpt":0.3012498438549492,"score_spread":0.276257806686716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}